their highest levels while coronary blood flow and of the 2 million deaths annually in the United States. plasma fibrinolytic activity are at their lowest levels of Coronary heart disease (CHD) (ie, myocardial infarction, the day. Moreover, BP rapidly rises from its nocturnal sudden death) account for the largest proportion (32%) nadir during the early morning hours. Prevention of of this mortality. Over the last 3 decades both CVD and pressure-related CVD events in hypertensive patients age-adjusted coronary death rates have fallen dramatiover the long term can be best accomplished by concally. However, crude CVD (and CHD) incidence is actutrolling BP throughout the 24 h time period with drugs ally increasing, almost exclusively as a function of risthat do not adversely impact (or favorably affect) other ing CVD incidence amongst older Americans. metabolic, neurohormonal, and hemostatic parameters. Population groups at highest for premature CVD compli-BP control (minimally to Ͻ140/90 mm Hg) may be partications include African-Americans, diabetics, men, cularly important in the early morning hours since elevsmokers, and those with high levels of single risk fac-
Introduction

Epidemiology of CVD and MI: a clinical perspective
Cardiovascular diseases (CVD) occur in epidemic proportions in most westernized societies such as Coronary heart disease (CHD) is the number one the US. While much can be accomplished with a killer of hypertensive patients over the long term public health/public policy population-based (Figure 1 ), 1 although both stroke and renal disease approach in regards to favorably modifying CVD risk have been perceived as 'pressure-related' CVD comfactors such as hypertension and hyperlipidemia, plications. The varied clinical presentations of CHD the clinician is most often placed in the situation of including myocardial infarction (MI) are highly attempting to reduce an individual patient's highprevalent in older patients of both sexes (Figures 2 risk status by pharmacological modification of identand 3). 2 Both hypertension and coronary atheroified risk factors. This brief overview will discuss sclerosis occur with increasing frequency with the epidemiology of CVD and hypertension and will advancing age. Left ventricular hypertrophy (LVH) attempt to link these data to important therapeutic also worsens the clinical outcome both of patients decisions facing the practitioner.
experiencing MI as well of those with occlusive coronary atherosclerosis.
3,4
The practitioner should be wary of several pervasive clinical myths regarding CHD: (1) African- fall in age-adjusted CHD death rates means that corMyth number 2 onary disease is on the decline. As with most myths CHD is by far the number one killer of both men and the following myths are based upon a kernel of truth women in the US. 2 CHD mortality is approximately which, unfortunately, have been presented to the 2-3 times more common than death from all forms practitioner in a context that does not facilitate optiof cancer in women. Men have higher CHD death mal clinical decision making.
rates than women; however, the total number of deaths is similar between the sexes because of the relatively greater number of older women than Myth number 1 men. 2 Clinically detectable CHD in women is CHD is the number one killer of African-Americans uncommon in premenopausal women, although the and whites.
2 In fact, the CHD mortality rate is practitioner should be aware of the at-risk younger approximately 20% higher 5 in African-American woman who has undergone surgical menopause. women compared to white women with virtually all Women also appear to experience greater mortality of the excess mortality occurring before 65 years of than men after acute MI. 9 The initial clinical presenage.
2 Amongst men CHD death rates are virtually tation of CHD differs between men and women. identical for African-Americans and whites.
5
Angina pectoris is the most common initial clinical Between 1976-1985 the decline in age-adjusted manifestation of CHD in women, whereas in men CHD death rates has been slower in the three of the angina more typically develops as a sequelae of MI. four major race-sex groups (except white males) MI also goes unrecognized more often in women than during the 1968-1975 time-period; in the racethan men. 9 Thus, the practitioner will encounter sex groups experiencing a slowing of the decline in CHD primarily in postmenopausal women who, on their age-adjusted CHD death rates, the rates are fallaverage, will be older and may have a different cliniing only half as fast. 5 Moreover, there is a lesser utilcal presentation than men. Also, non-invasive diagization of coronary angiography and coronary artery nostic testing has a low sensitivity for detecting corbypass grafting for coronary ischemia attributable to onary ischemia when utilized in women. CHD large-vessel atherosclerosis in African-Americans prevention takes on added importance in women compared to whites, even access to these procedures given the lesser clinical recognition of MI in women is similar.
6 African-Americans appear to be at a sevas well as their higher mortality risk after an acute eral-fold greater risk of sudden death than whites. 7, 8 MI. The available epidemiological data suggest that African-Americans have at least as much, and possMyth number 3 ibly more, CHD than whites. The practitioner should therefore have a heightened suspicion regarding the Age-adjusted CHD death rates in the US have been falling since around 1968.
Nevertheless, agepresence of CHD in African-American patients.
adjusted CHD death rates are not actual rates. Howagainst a multiplicity of pressure-related complications. [18] [19] [20] ever, they fit the purpose of making two populations comparable even if their age structures are different. Age-adjusted rates are derived by applying the ageDoes pharmacological lowering of BP cause MI? specific CHD death rates of the current population of interest to a reference population (ie, 1940 US Some investigators have reported the existence of a J-or U-shaped relationship between DBP level and population). The reference population virtually always has a different age distribution, that is on the risk of subsequent CHD mortality, most often in older MI survivors and/or in patients with clinically averge, younger than the current population of interest. Therefore age-adjusted death rates may be lower detectable CHD. 12, 21, 22 Thus, concern has surfaced about the clinical wisdom of pharmacological BP even though the actual number of deaths is increasing. However, age-adjusted death rates do not neceslowering in patients with pre-existing coronary disease. There is little doubt that the J-curve exists in sarily mirror crude death rates, the actual number of deaths a particular population experiences. The selected older populations with vascular disease. Nevertheless, the simple demonstration of an associcrude heart disease death rate actually increased 2.5% during the 1993 calendar year with the 65 and ation between low DBP and CHD does in no way prove a cause and effect relationship. Indeed, there older age group being responsible for 95% of the increase.
2 is considerable evidence against the thesis that the association of low DBP actually causes MI. First, it Despite the impressive declines in age-adjusted CHD death rates over the years, heart disease has been shown in older adults with ISH (ISH, SBP у160 and DBP Ͻ90 mm Hg) that a DBP Ͻ75 mm Hg remains, by far, the number one cause of diseasespecific morbidity and mortality in the US adult is associated with an approximate five-fold increase in the odds of carotid atherosclerosis as measured population, both amongst normotensives and hypertensives. The practitioner will encounter a steadily by B-mode ultrasonography. 23 These data suggest that the wide pulse pressure (SBP-DBP) in older increasing burden of clinical CHD because of at least three factors: (1) the aging of the US population and adults with high levels of SBP is probably a marker for vascular atherosclerosis. Second, pharmacologithe positive association of age with CHD; (2) our success in preventing premature CHD and delaying cal treatment of these same individuals increases the likelihood of disease-free survival (fewer CVD its initial onset into the older age groups; and (3) the steady improvements in mortality risk reduction events), the same protective effect that was observed amongst those with ISH and no evidence of carotid from acute MI and other forms of ischemic heart disease.
atherosclerosis. 24 Third, even amongst MI survivors the J-shaped association between CHD and DBP is time-limited with the long-term risk (16 years) of
Hypertension and CVD
both CHD and all-cause mortality being more closely correlated to the baseline level of SBP than DBP.
12
At least 43 million adults in the US have hypertension (SBP у140 or DBP у90 mm Hg and/or taking How should the practitioner use this information? First, the overwhelming preponderance of data sug-BP medication). 10 The clinical importance of hypertension relates not only to the fact that so many gests that gradual BP lowering (minimally to Ͻ140/90 mm Hg) is beneficial and, importantly, not people are affected but also because the risk of CVD morbid and fatal events including stroke, myocarharmful in hypertensive patients. On the other hand, rapid BP reductions should be avoided dial infarction, congestive heart failure (CHF), renal insufficiency, is directly linked to the height of the because of the real potential for precipitating targetorgan ischemia (ie, angina, TIA, stroke). Second, the blood pressure (BP) elevation.
1,11-13 The level of systolic BP (SBP) appears to be more closely linked physician should pay close attention to the SBP level when making decisions regarding initiation of than diastolic BP (DBP) to CHD morbidity and mortality.
12,14,15 Indeed, DBP is 'normal' (Ͻ90 mm Hg) in treatment as well as when evaluating the success of treatment. Third, evidence of BP-related TOD isolated systolic hypertension (ISH), the most lethal form of hypertension in terms of CVD risk and allshould be sought during the initial and occasionally during interim clinical evaluations of the hypertencause mortality. Isolated systolic hypertension is uncommon prior to 55 years of age but is the most sive patient. This is because pressure-related TOD portends a significantly higher risk of CVD complicommonly encountered form of hypertension after age 70 because of the age-related disproportionate cations within a shorter time-frame, thus the potential benefits of treatment are greater. Conversely, the rise in SBP relative to DBP. Hypertensives with evidence of BP-related target-organ damage (TOD) (ie, risks of no or inadequate treatment are also considerably higher in hypertensives with BP-related LVH, hypercreatinemia) and/or vascular atherosclerosis are at significantly greater risk for CVD mor-TOD. bidity and mortality than are hypertensives with similar levels of BP without BP-related TOD or
Timing of CVD and MI clinical events
atherosclerosis. 16, 17 Hypertension identification and treatment rates have improved over the years; how-MI and other atherothrombotic/ischemic events such as stroke and sudden cardiac death as well as transiever, only 55% of drug treated hypertensives have attained a BP Ͻ140/90 mm Hg. 10 It is well estabent myocardial ischemia do not randomly occur throughout the 24-h period. These clinical events lished that pharmacological lowering of BP protects hypertensive patients across a broad age range have a peak incidence in the morning hours as they occur most often between 6 am and noon. [25] [26] [27] [28] In one Summary study of asymptomatic hypertensives with ambulat-BP control has been shown to improve survival and ory ischemia (ST-segment depression) the 24-h to lessen the risk of pressure-related complications ambulatory BP burden was greater in hypertensives in hypertensive patients. However, once the with ambulatory ischemia compared to hypertendecision has been made to initiate antihypertensive sives without transient myocardial ischemia. 26 Trantreatment the clinician must decide which antihysient myocardial ischemia is also more likely to pertensive drug(s) to utilize. A generic issue that occur when the heart rate thresholds for triggering cuts across antihypertensive drug class is one aspect ST-segment depression are exceeded during mornof the pharmacokinetic profile of antihypertensive ing as compared to evening hours. 29 Rocco and drugs. That is, the duration of action of these agents. coworkers 30 have also shown that episodes of ambuTruly long-acting antihypertensives are less prone to latory ischemia further cluster within the 4 h a loss of BP control at trough (just before the next immediately after awakening and the assumption of scheduled dose) and, in intermittently non-comnormal daily activities.
pliant patients, their offset of action is slow leading to greater BP control during the time interval between the missed dose and the next dose of medication that the patient takes. Given the high inciWhy do CVD events cluster in the dence of ischemic events during the early morning morning hours?
hours it seems logical not only to use enough longacting drug(s) to control BP throughout the day but Is the early morning peak occurrence of to give due consideration to night time rather than atherothrombotic/ischemic coronary and cerebrovamorning dosing of antihypertensive agents. scular events explainable by plausible biological phenomena? The totality of evidence suggests that multiple hemodynamic, neurohumoral, and hemo- their nadir during the early morning hours then rap- 
